RPGR-Related Retinopathy: Clinical Features, Molecular Genetics, and Gene Replacement Therapy
- PMID: 37188525
- PMCID: PMC10626266
- DOI: 10.1101/cshperspect.a041280
RPGR-Related Retinopathy: Clinical Features, Molecular Genetics, and Gene Replacement Therapy
Abstract
Retinitis pigmentosa GTPase regulator (RPGR) gene variants are the predominant cause of X-linked retinitis pigmentosa (XLRP) and a common cause of cone-rod dystrophy (CORD). XLRP presents as early as the first decade of life, with impaired night vision and constriction of peripheral visual field and rapid progression, eventually leading to blindness. In this review, we present RPGR gene structure and function, molecular genetics, animal models, RPGR-associated phenotypes and highlight emerging potential treatments such as gene-replacement therapy.
Copyright © 2023 Cold Spring Harbor Laboratory Press; all rights reserved.
Figures
References
-
- Beltran WA, Cideciyan A, Lewin AS, Iwabe S, Khanna H, Sumaroka A, Chiodo VA, Fajardo DS, Román AJ, Deng WT, et al. 2012. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci 109: 2132–2137. 10.1073/pnas.1118847109 - DOI - PMC - PubMed
-
- Beltran WA, Cideciyan A, Iwabe S, Swider M, Kosyk MS, McDaid K, Martynyuk I, Ying GS, Shaffer J, Deng WT, et al. 2015. Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease. Proc Natl Acad Sci 112: E5844–E5853. 10.1073/pnas.1509914112 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources